Literature DB >> 1469104

Human Toxoplasma gondii-specific secretory immunoglobulin A reduces T. gondii infection of enterocytes in vitro.

D G Mack1, R McLeod.   

Abstract

Whey from 17 women (four acutely infected with Toxoplasma gondii, eight chronically infected, and five uninfected) was studied. T. gondii-specific secretory IgA antibodies were demonstrated by ELISA in whey from acutely infected and one of eight chronically infected women. Such antibodies to tachyzoite proteins of < or = 14, 22, 26-28, 30, 46, 60, 70-80, and > 100 kD (eliminated by protease but not periodate or neuraminidase treatment) were demonstrated in whey from acutely infected subjects when Western blots were probed with their whey and antibodies to human secretory IgA or IgA or secretory piece. Secretory IgA from four of eight chronically infected women recognized the 46- and 69-kD epitopes. Other whey samples were negative. Incubation of T. gondii tachyzoites with whey or purified secretory IgA from acutely infected (but not seronegative) women caused 50-75% reduction in infection of enterocytes in vitro. Whey reactive with the 46-kD epitope from three of six chronically infected women caused less (> or = 40%) inhibition. Whey and purified secretory IgA from two of three acutely infected women agglutinated tachyzoites. Whey did not result in complement-dependent lysis of T. gondii. These results indicate that it may be possible to produce human secretory IgA to T. gondii capable of reducing initial infection of enterocytes, as such IgA is present during natural infection. They also demonstrate candidate epitopes for such protection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469104      PMCID: PMC443418          DOI: 10.1172/JCI116153

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Remission of diarrhoea due to cryptosporidiosis in an immunodeficient child treated with hyperimmune bovine colostrum.

Authors:  S Tzipori; D Roberton; C Chapman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-15

2.  Toxoplasma gondii: the role of a 30-kDa surface protein in host cell invasion.

Authors:  J Grimwood; J E Smith
Journal:  Exp Parasitol       Date:  1992-02       Impact factor: 2.011

3.  Hyperimmune bovine colostrum neutralizes Cryptosporidium sporozoites and protects mice against oocyst challenge.

Authors:  R Fayer; L E Perryman; M W Riggs
Journal:  J Parasitol       Date:  1989-02       Impact factor: 1.276

4.  Jacalin: an IgA-binding lectin.

Authors:  M C Roque-Barreira; A Campos-Neto
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

5.  Immunity to enterotoxigenic Escherichia coli.

Authors:  M M Levine; D R Nalin; D L Hoover; E J Bergquist; R B Hornick; C R Young
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

6.  Immune response of mice to ingested Toxoplasma gondii: a model of toxoplasma infection acquired by ingestion.

Authors:  R McLeod; R G Estes; D G Mack; H Cohen
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

7.  Protection against cholera in breast-fed children by antibodies in breast milk.

Authors:  R I Glass; A M Svennerholm; B J Stoll; M R Khan; K M Hossain; M I Huq; J Holmgren
Journal:  N Engl J Med       Date:  1983-06-09       Impact factor: 91.245

8.  Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins.

Authors:  C Mietens; H Keinhorst; H Hilpert; H Gerber; H Amster; J J Pahud
Journal:  Eur J Pediatr       Date:  1979       Impact factor: 3.183

9.  Specific immune response in the respiratory tract after administration of an oral polyvalent bacterial vaccine.

Authors:  R L Clancy; A W Cripps; A J Husband; D Buckley
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

10.  Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG.

Authors:  H P Taylor; N J Dimmock
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

View more
  9 in total

1.  Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection.

Authors:  N Debard; D Buzoni-Gatel; D Bout
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

2.  Counter-protective role for interleukin-5 during acute Toxoplasma gondii infection.

Authors:  M B Nickdel; F Roberts; F Brombacher; J Alexander; C W Roberts
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

3.  B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii.

Authors:  P C Sayles; G W Gibson; L L Johnson
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Toxoplasma gondii Infection Decreases Intestinal 5-Lipoxygenase Expression, while Exogenous LTB4 Controls Parasite Growth.

Authors:  Ester Cristina Borges Araujo; Marisol Patricia Pallete Briceño; Yusmaris Cariaco; Mário Cézar Oliveira; Marcos Paulo Oliveira Almeida; Natália Carnevalli de Miranda; Neide Maria Silva
Journal:  Infect Immun       Date:  2022-06-06       Impact factor: 3.609

5.  Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.

Authors:  Kamal El Bissati; Aziz A Chentoufi; Paulette A Krishack; Ying Zhou; Stuart Woods; Jitender P Dubey; Lo Vang; Joseph Lykins; Kate E Broderick; Ernest Mui; Yasuhiro Suzuki; Qila Sa; Stephanie Bi; Nestor Cardona; Shiv K Verma; Laura Fraczek; Catherine A Reardon; John Sidney; Jeff Alexander; Alessandro Sette; Tom Vedvick; Chris Fox; Jeffrey A Guderian; Steven Reed; Craig W Roberts; Rima McLeod
Journal:  JCI Insight       Date:  2016-09-22

6.  In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii.

Authors:  E Holfels; J McAuley; D Mack; W K Milhous; R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

7.  Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice.

Authors:  Angelika Wagner; Irma Schabussova; Bärbel Ruttkowski; Roman Peschke; Józef Kur; Michael Kundi; Anja Joachim; Ursula Wiedermann
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

8.  Protective immunity induced by peptides of AMA1, RON2 and RON4 containing T-and B-cell epitopes via an intranasal route against toxoplasmosis in mice.

Authors:  Tie-E Zhang; Li-Tian Yin; Run-Hua Li; Hai-Long Wang; Xiao-Li Meng; Guo-Rong Yin
Journal:  Parasit Vectors       Date:  2015-01-13       Impact factor: 3.876

9.  Orally Administrated Recombinant Vaccinia Virus Displaying ROP4 Induces Protection against Toxoplasma gondii Challenge Infection.

Authors:  Keon-Woong Yoon; Ki-Back Chu; Hae-Ji Kang; Min-Ju Kim; Gi-Deok Eom; Fu-Shi Quan
Journal:  Vaccines (Basel)       Date:  2022-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.